Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
765.370.36%
QQQ
714.590.51%
BTC/USD
76609.024.9302%
DIA
529.990.55%
GLD
420.451.25%
TLT
82.200.17%

Aligos Therapeutics Inc

ALGSNASDAQ
Trade with Public
Trade with Public
$6.91
0.477.3%
Last update: Aug 19, 4:26 PM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Aligos Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aligos Therapeutics (ALGS).

Price Target Range — 6 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingBuy# Analysts6Avg. Consensus PT$43Upside to Avg. PT+522.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 28, 2026Lake StreetDaniel BrimsInitiateBuy$45
May 21, 2026Cantor FitzgeraldSteve SeedhouseInitiateOverweight$20
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $45.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Overweight rating and announces Price Target of $20.
Benzinga Newsdesk

PRO
WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

WestPark Capital initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $48.
Benzinga Newsdesk

PRO
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

Jefferies analyst Anthea Li assumes Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and lowers Price Target of $48.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Aligos Therapeutics (NASDAQ:ALGS) with a Buy and maintains $50 price target.
Benzinga Newsdesk

PRO
UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20

UBS analyst Michael Yee initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $20.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved